Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Camila Xu -- 1395 2022-11-02 01:32:44

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. GSK-3 Inhibitor. Encyclopedia. Available online: https://encyclopedia.pub/entry/32522 (accessed on 25 September 2026).
HandWiki. GSK-3 Inhibitor. Encyclopedia. Available at: https://encyclopedia.pub/entry/32522. Accessed September 25, 2026.
HandWiki. "GSK-3 Inhibitor" Encyclopedia, https://encyclopedia.pub/entry/32522 (accessed September 25, 2026).
HandWiki. (2022, November 02). GSK-3 Inhibitor. In Encyclopedia. https://encyclopedia.pub/entry/32522
HandWiki. "GSK-3 Inhibitor." Encyclopedia. Web. 02 November, 2022.
GSK-3 Inhibitor
Edit
The content is sourced from: https://handwiki.org/wiki/Biology:GSK-3_inhibitor

Glycogen synthase, an enzyme that is responsible in glycogen synthesis, is activated by glucose 6-phosphate (G6P), and inhibited by glycogen synthase kinases (GSK3). Those two mechanisms play an important role in glycogen metabolism. Glycogen synthase kinase (GSK-3) is a serine/threonine kinase that phosphorylate either threonine or serine, and this phosphorylation permits a variety of biological activities as glycogen metabolism, cell signaling, cellular transport, and others. GS inhibition by GSK-3β leads to a decrease in glycogen synthesis in the liver and muscles, along with increased blood glucose or hyperglycemia. This is why GSK-3β is associated with the pathogenesis and progression of many diseases, such as diabetes, obesity, and cancer. Human GSK-3 has two isoforms, α and β. It is active in resting cells and is inhibited by several hormones such as insulin, endothelial growth factor, and platelet-derived growth factor. Insulin inactivates it by phosphorylation of the specific serine residues Ser21 and Ser9 in GSK-3 isoforms α and β, respectively. In a phosphatidylinositol 3-kinase-dependent way. Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.

glycogen synthesis glycogen synthase phosphatidylinositol

References

  1. "Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation". Journal of Biochemical and Molecular Toxicology 27 (9): 425–36. September 2013. doi:10.1002/jbt.21503. PMID 23784744.  https://dx.doi.org/10.1002%2Fjbt.21503
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415316/
  3. "Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation". European Journal of Pharmacology 584 (1): 185–91. April 2008. doi:10.1016/j.ejphar.2008.01.019. PMID 18295757.  https://dx.doi.org/10.1016%2Fj.ejphar.2008.01.019
  4. Eldar-Finkelman, H. and Martinez, A. (2018). GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.
  5. "Effects of Ranitidine, Famotidine and Omeprazole on Some Haematobiochemical Parameters in Mice". Journal of Animal and Veterinary Advances 2: 321–6. 2003. http://medwelljournals.com/abstract/?doi=javaa.2003.321.326. 
  6. "Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation". Journal of Enzyme Inhibition and Medicinal Chemistry 28 (4): 690–4. August 2013. doi:10.3109/14756366.2012.672413. PMID 22512725.  https://dx.doi.org/10.3109%2F14756366.2012.672413
  7. "Multiple biological activities of curcumin: a short review". Life Sciences 78 (18): 2081–7. March 2006. doi:10.1016/j.lfs.2005.12.007. PMID 16413584.  https://dx.doi.org/10.1016%2Fj.lfs.2005.12.007
  8. Balasubramanian, Krishnan (2006). "Molecular Orbital Basis for Yellow Curry Spice Curcumin's Prevention of Alzheimer's Disease". Journal of Agricultural and Food Chemistry 54 (10): 3512–3520. doi:10.1021/jf0603533.  https://dx.doi.org/10.1021%2Fjf0603533
  9. "NMR study of the solution structure of curcumin". Journal of Natural Products 70 (2): 143–6. February 2007. doi:10.1021/np060263s. PMID 17315954.  https://dx.doi.org/10.1021%2Fnp060263s
  10. "Curcumin: A natural antiinflammatory agent". Indian Journal of Pharmacology 37 (3): 141. 2005. doi:10.4103/0253-7613.16209. http://www.bioline.org.br/pdf?ph05037. 
  11. "Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture". Journal of Agricultural and Food Chemistry 47 (10): 4297–300. October 1999. doi:10.1021/jf990308d. PMID 10552805.  https://dx.doi.org/10.1021%2Fjf990308d
  12. "Enhancement of wound healing by curcumin in animals". Wound Repair and Regeneration 6 (2): 167–77. 1998. doi:10.1046/j.1524-475X.1998.60211.x. PMID 9776860.  https://dx.doi.org/10.1046%2Fj.1524-475X.1998.60211.x
  13. "Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo". The Journal of Biological Chemistry 280 (7): 5892–901. February 2005. doi:10.1074/jbc.M404751200. PMID 15590663.  https://dx.doi.org/10.1074%2Fjbc.M404751200
  14. "Synthesis and exploration of novel curcumin analogues as anti-malarial agents". Bioorganic & Medicinal Chemistry 16 (6): 2894–902. March 2008. doi:10.1016/j.bmc.2007.12.054. PMID 18194869.  https://dx.doi.org/10.1016%2Fj.bmc.2007.12.054
  15. "Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats". Clinical and Experimental Pharmacology & Physiology 33 (10): 940–5. October 2006. doi:10.1111/j.1440-1681.2006.04468.x. PMID 17002671.  https://dx.doi.org/10.1111%2Fj.1440-1681.2006.04468.x
  16. "Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability". The Journal of Biological Chemistry 278 (41): 39583–90. October 2003. doi:10.1074/jbc.M305676200. PMID 12871932.  https://dx.doi.org/10.1074%2Fjbc.M305676200
  17. "Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation". Journal of Enzyme Inhibition and Medicinal Chemistry 24 (3): 771–8. June 2009. doi:10.1080/14756360802364377. PMID 18720192.  https://dx.doi.org/10.1080%2F14756360802364377
  18. "Antipsychotics A-Z". Mind.org.uk. 2018. https://www.mind.org.uk/information-support/drugs-and-treatments/antipsychotics-a-z. 
  19. "Antipsychotic Medication for Bipolar Disorder". WebMD. https://www.webmd.com/bipolar-disorder/guide/antipsychotic-medication. 
  20. "Characterization of olanzapine-induced weight gain in rats". Journal of Psychopharmacology 16 (4): 291–6. December 2002. doi:10.1177/026988110201600402. PMID 12503827.  https://dx.doi.org/10.1177%2F026988110201600402
  21. "Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia". Neuropsychiatric Disease and Treatment 6: 573–81. September 2010. doi:10.2147/NDT.S5463. PMID 20856920.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2938306
  22. Murphy, Felicity; Middleton, Mark (2012). "Cytostatic and cytotoxic drugs". A worldwide yearly survey of new data in adverse drug reactions and interactions. Side Effects of Drugs Annual. 34. pp. 731–747. doi:10.1016/B978-0-444-59499-0.00045-3. ISBN 9780444594990.  https://dx.doi.org/10.1016%2FB978-0-444-59499-0.00045-3
  23. "Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models". International Journal of Alzheimer's Disease 2012: 381029. 2012. doi:10.1155/2012/381029. PMID 22888461.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3408674
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 1.5K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 02 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback